MedTrace Logo

Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer

NCT00002866 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2020-04-01

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as G-CSF may increase the number of immune cells found in bone marrow or peripheral blood and may help a person 's immune system recover from the side effects of chemotherapy.

PURPOSE: Phase I/II trial to study the effectiveness of docetaxel and epirubicin with and without G-CSF in treating women with metastatic breast cancer.

Conditions

Interventions

BIOLOGICAL

filgrastim

DRUG

docetaxel

DRUG

epirubicin hydrochloride

Sponsors & Collaborators

  • NCIC Clinical Trials Group

    lead NETWORK

Principal Investigators

  • Maureen E. Trudeau, BSc, MA, MD, FRCPC · Toronto Sunnybrook Regional Cancer Centre

Study Design

Purpose
TREATMENT

Eligibility

Min Age
16 Years
Max Age
120 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-08-12
Primary Completion
2005-07-19
Completion
2009-12-21

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002866 on ClinicalTrials.gov